A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers
Clinical trial NCT03547037 · COMPLETED
Trial details
- NCT number
- NCT03547037
- Sponsor
- Janssen Pharmaceutical K.K.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-31
- Primary completion
- 2022-07-04
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.